Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma

References

• Kyle RA, Rajkumar SV. Multiple myeloma. New Eng J Med 2004; 351:1860-73; PMID:15509819; http://dx.doi.org/10.1056/NEJMra041875
   PubMed Web of Science ®Google Scholar
• Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011; 183:25-35
   PubMedGoogle Scholar
• Briani C, Berno T, Campagnolo M, Zambello R. Lenalidomide for bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol 2010; 7:289-94; PMID:20824906
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010; 24:1769-78; PMID:20739955; http://dx.doi.org/10.1038/leu.2010.175
   PubMed Web of Science ®Google Scholar
• Moreau P, Hulin C, Facon T. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. Hematol Oncol Clin North Am 2014; 28:829-38; PMID:25212885
   PubMed Web of Science ®Google Scholar
• Kumar S. Stem cell transplantation for multiple myeloma. Curr Opin Oncol 2009; 21:162-70
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma 2013; 54:555-60; PMID:22881043; http://dx.doi.org/10.3109/10428194.2012.719614
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991; 88:62-6; PMID:2056131; http://dx.doi.org/10.1172/JCI115305
   PubMed Web of Science ®Google Scholar
• Ren S, Johnson BG, Kida Y, Ip C, Davidson KC, Lin SL, Kobayashi A, Lang RA, Hadjantonakis AK, Moon RT, et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci U S A 2013; 110:1440-5; PMID:23302695; http://dx.doi.org/10.1073/pnas.1211179110
   PubMed Web of Science ®Google Scholar
• Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD, Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008; 42:669-80; PMID:18294945; http://dx.doi.org/10.1016/j.bone.2007.12.006
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Eng J Med 2003; 349:2483-94; PMID:14695408; http://dx.doi.org/10.1056/NEJMoa030847
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32:290-2
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109:2106-11; PMID:17068150; http://dx.doi.org/10.1182/blood-2006-09-047712
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009; 114:371-9; PMID:19417213; http://dx.doi.org/10.1182/blood-2008-11-191577
   PubMed Web of Science ®Google Scholar
• Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Ann Rev Pathol 2014; 9:287-314; PMID:24079833; http://dx.doi.org/10.1146/annurev-pathol-012513-104715
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nature Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51:881-90; PMID:20146264
   PubMed Web of Science ®Google Scholar
• Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y, et al. miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostat Dis 2010; 13:356-61; PMID:20820187; http://dx.doi.org/10.1038/pcan.2010.32
   PubMed Web of Science ®Google Scholar
• Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted players. Mol Cancer 2013; 12:43; PMID:23683438; http://dx.doi.org/10.1186/1476-4598-12-43
   PubMed Web of Science ®Google Scholar
• Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 2013; 5:3-13; PMID:22935141; http://dx.doi.org/10.1093/jmcb/mjs049
   PubMed Web of Science ®Google Scholar
• Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010; 101:241-9; PMID:19891660; http://dx.doi.org/10.1111/j.1349-7006.2009.01385.x
   PubMed Web of Science ®Google Scholar
• Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, Inazawa J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71:6450-62; PMID:21868754; http://dx.doi.org/10.1158/0008-5472.CAN-11-0364
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y, Xu HM. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep 2012; 27:447-54; PMID:21971665
   PubMed Web of Science ®Google Scholar
• Rio-Machin A, Ferreira BI, Henry T, Gomez-Lopez G, Agirre X, Alvarez S, Rodriguez-Perales S, Prosper F, Calasanz MJ, Martínez J, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia 2013; 27:925-31; PMID:23174883; http://dx.doi.org/10.1038/leu.2012.302
   PubMed Web of Science ®Google Scholar
• Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007; 110:1587-94; PMID:17515399; http://dx.doi.org/10.1182/blood-2007-03-082529
   PubMed Web of Science ®Google Scholar
• Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24:986-91; PMID:16293576; http://dx.doi.org/10.1634/stemcells.2005-0220
   PubMed Web of Science ®Google Scholar
• Chng WJ, Lau LG, Yusof N, Mow BM. Targeted therapy in multiple myeloma. Cancer Control 2005; 12:91-104; PMID:15855892
   PubMedGoogle Scholar
• Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet 2013; 14:535-48; PMID:23817310; http://dx.doi.org/10.1038/nrg3471
   PubMed Web of Science ®Google Scholar
• Bi C, Chng WJ. MicroRNA: important player in the pathobiology of multiple myeloma. Biomed Res Int 2014; 2014:521586; PMID:24991558; http://dx.doi.org/10.1155/2014/521586
   PubMed Web of Science ®Google Scholar
• Ahmad N, Haider S, Jagannathan S, Anaissie E, Driscoll JJ. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia 2014; 28:732-8; PMID:24714346; http://dx.doi.org/10.1038/leu.2013.262
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Gimsing P, Gronbaek K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol 2013; 91:95-105; PMID:23586898; http://dx.doi.org/10.1111/ejh.12124
   PubMed Web of Science ®Google Scholar
• Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Fermiñán E, Martín-Jiménez P, Chillón C, Risueño A, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24:629-37; PMID:20054351; http://dx.doi.org/10.1038/leu.2009.274
   PubMed Web of Science ®Google Scholar
• Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12:838-46; PMID:22671926; http://dx.doi.org/10.2174/156800912802429355
   PubMed Web of Science ®Google Scholar
• Palagani A, Op de Beeck K, Naulaerts S, Diddens J, Sekhar Chirumamilla C, Van Camp G, Laukens K, Heyninck K, Gerlo S, Mestdagh P, et al. Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. PLoS One 2014; 9:e113842
   PubMed Web of Science ®Google Scholar
• Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ, Li QF, Chen XQ, Wang LS. Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl−1. Biochem Biophys Res Commun 2011; 414:233-9; PMID:21951844; http://dx.doi.org/10.1016/j.bbrc.2011.09.063
   PubMed Web of Science ®Google Scholar
• Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 2015; 29(5):1004-17; PMID:25541152
   PubMed Web of Science ®Google Scholar
• Postberg J, Kanders M, Forcob S, Willems R, Orth V, Hensel KO, Weil PP, Wirth S, Jenke AC. CpG signalling, H2A.ZH3 acetylation and microRNA-mediated deferred self-attenuation orchestrate foetal NOS3 expression. Clin Epigenetics 2015; 7:9; PMID:25699114
   PubMed Web of Science ®Google Scholar
• Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11:228-34; PMID:19255566; http://dx.doi.org/10.1038/ncb0309-228
   PubMed Web of Science ®Google Scholar
• Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A. MicroRNAs, macrocontrol: regulation of miRNA processing. RNA 2010; 16:1087-95; PMID:20423980; http://dx.doi.org/10.1261/rna.1804410
   PubMed Web of Science ®Google Scholar
• Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 2011; 12:19-31; PMID:21116305 http://dx.doi.org/10.1038/nrg2916
   PubMed Web of Science ®Google Scholar
• Langhe R, Norris L, Saadeh FA, Blackshields G, Varley R, Harrison A, Gleeson N, Spillane C, Martin C, O'Donnell DM, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett 2015; 356:628-36; PMID:25451316; http://dx.doi.org/10.1016/j.canlet.2014.10.010
   PubMed Web of Science ®Google Scholar
• Taipaleenmaki H, Bjerre Hokland L, Chen L, Kauppinen S, Kassem M. Mechanisms in endocrinology: micro-RNAs: targets for enhancing osteoblast differentiation and bone formation. Eur J Endocrinol 2012; 166:359-71; PMID:22084154
   PubMed Web of Science ®Google Scholar
• Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S, Lapointe R. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007; 96:646-53; PMID:17245340; http://dx.doi.org/10.1038/sj.bjc.6603579
   PubMed Web of Science ®Google Scholar
• Liddell K. Smell as a diagnostic marker. Postgrad Med J 1976; 52:136-8
   PubMed Web of Science ®Google Scholar
• Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010; 285:25221-31; PMID:20551325; http://dx.doi.org/10.1074/jbc.M110.116137
   PubMed Web of Science ®Google Scholar
• Zhou AD, Diao LT, Xu H, Xiao ZD, Li JH, Zhou H, Qu LH. Beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway. Oncogene 2012; 31:2968-78; PMID:22020335
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Oliver L, Le Gouill S, Bataille R, Amiot M. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl−1 and Bim and a decrease in the Mcl−1/Bim complex. Oncogene 2005; 24:8076-9; PMID:16091744; http://dx.doi.org/10.1038/sj.onc.1208949
   PubMed Web of Science ®Google Scholar
• Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther 2012; 11:1781-8; PMID:22653969; http://dx.doi.org/10.1158/1535-7163.MCT-11-0949
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114:3625-8; PMID:19710503; http://dx.doi.org/10.1182/blood-2009-05-220285
   PubMed Web of Science ®Google Scholar
• Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010; 16:5079-86; PMID:20739431; http://dx.doi.org/10.1158/1078-0432.CCR-10-1662
   PubMed Web of Science ®Google Scholar
• Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 2003; 8:337-43; PMID:12815276; http://dx.doi.org/10.1023/A:1024164700094
   PubMed Web of Science ®Google Scholar
• George SK, Tovar-Sepulveda V, Shen SS, Jian W, Zhang Y, Hilsenbeck SG, Lerner SP, Smith CL. Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. Transl Oncol 2013; 6:244-55; PMID:23730403; http://dx.doi.org/10.1593/tlo.13247
   PubMed Web of Science ®Google Scholar
• Furuya Y, Inagaki A, Khan M, Mori K, Penninger JM, Nakamura M, Udagawa N, Aoki K, Ohya K, Uchida K, et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kappaB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem 2013; 288:5562-71; PMID:23319583; http://dx.doi.org/10.1074/jbc.M112.426080
   PubMed Web of Science ®Google Scholar